Safety and efficacy of COVID‐19 convalescent plasma in severe pulmonary disease: A report of 17 patients

Pal, Prem; Ibrahim, Moayed; Niu, Alex; Zwezdaryk, Kevin J.; Tatje, Elise; Robinson, William R.; Ko, Leta; Satyavarapu, Ishwarya; Jones, Wallace; Nachabe, Adeem; Luk, Alfred; Mushatt, David; Halvorson, Karin; Denson, Joshua L.; Smith, Charles C.; Simeone, Francesco; Davis, Gaynelle; Gill, Sukhmani; McDougal, April; Vigh, Aniko S.; Peterson, Tim; Ning, Bo; Hu, Tony; Socola, Francisco; Robinson, James E.; Safah, Hana; Saba, Nakhle S.

doi:10.1111/tme.12729

Cited by 15 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new randomized clinical trial of COVID-19 convalescent plasma therapy reported that the transfusion in patients with severe COVID-19 pneumonia improved clinical symptoms [ 16 ]. Also of note, Young et al revealed that after convalescent plasma transfusion, the inflammatory indicators in patients with COVID-19 pneumonia decreased significantly, while the oxyhemoglobin saturation gradually increased to a normal level [ 17 ]. All of these findings support the results of our current study.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China

et al. 2020

View full text Add to dashboard Cite

Background This retrospective study aimed to describe the effects of convalescent plasma therapy in 24 patients diagnosed with coronavirus disease 2019 (COVID-19) pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during February and March 2020 in Wuhan, China. Materia/Methods The confirmation of SARS-CoV-2 infection was made by the reverse transcription-polymerase chain reaction test. We retrospectively analyzed the clinical data and laboratory test reports of patients with severe COVID-19 pneumonia who received a convalescent plasma transfusion. Results A total of 24 patients with COVID-19 pneumonia who were transfused with ABO-compatible convalescent plasma were enrolled in the study. Convalescent plasma transfusion showed an effective clinical outcome in 14 of 24 patients (an effective rate of 58.3%). No patients had an adverse reaction to the transfusion. Compared with before convalescent plasma transfusion, the lymphocyte count after convalescent plasma transfusion increased to a normal level (median: 0.80×10 9 /L vs. 1.12×10 9 /L, P =0.004). Other laboratory indicators such as white blood cells, high-sensitivity C-reactive protein, procalcitonin, alanine aminotransferase, and aspartate transaminase showed a decreasing trend after transfusion. Conclusions This retrospective observational clinical study showed that convalescent plasma therapy could have beneficial effects on patient outcomes. Recently, regulatory authorization has been given for the use of convalescent plasma therapy, and clinical guidelines have been developed for the collection and use of convalescent plasma and hyperimmune immunoglobulin in patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China

et al. 2020

View full text Add to dashboard Cite

show abstract

“…She was weaned off high-flow nasal cannula within 48 h and within a few days was discharged home in stable condition. 32…”

mentioning

confidence: 99%

Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency

Senefeld

Klassen

Ford

et al. 2020

Preprint

View full text Add to dashboard Cite

0AbstractIn the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.

show abstract

“…All studies that assessed adverse events have reported no or minimal adverse events [102,206]. Of major interest is one of the first large trials published so far-concerning the safety of 5000 recipients-that has identified only limited and nonunexpected transfusion complications [95].…”

Section: Safetymentioning

confidence: 99%

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng¹,

Rhind²,

Beckett³

2021

JMIR Public Health Surveill

View full text Add to dashboard Cite

Background The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2, has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following recovery from COVID-19 infection and development of antibodies against the virus is an attractive option for either prophylactic or therapeutic treatment, since antibodies may have direct or indirect antiviral activities and immunotherapy has proven effective in principle and in many clinical reports. Objective We seek to characterize the latest advances and evidence in the use of CP for COVID-19 through a systematic review and quantitative analysis, identify knowledge gaps in this setting, and offer recommendations and directives for future research. Methods PubMed, Web of Science, and Embase were continuously searched for studies assessing the use of CP for COVID-19, including clinical studies, commentaries, reviews, guidelines or protocols, and in vitro testing of CP antibodies. The screening process and data extraction were performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Quality appraisal of all clinical studies was conducted using a universal tool independent of study designs. A meta-analysis of case-control and randomized controlled trials (RCTs) was conducted using a random-effects model. Results Substantial literature has been published covering various aspects of CP therapy for COVID-19. Of the references included in this review, a total of 243 eligible studies including 64 clinical studies, 79 commentary articles, 46 reviews, 19 guidance and protocols, and 35 in vitro testing of CP antibodies matched the criteria. Positive results have been mostly observed so far when using CP for the treatment of COVID-19. There were remarkable heterogeneities in the CP therapy with respect to patient demographics, donor antibody titers, and time and dose of CP administration. The studies assessing the safety of CP treatment reported low incidence of adverse events. Most clinical studies, in particular case reports and case series, had poor quality. Only 1 RCT was of high quality. Randomized and nonrandomized data were found in 2 and 11 studies, respectively, and were included for meta-analysis, suggesting that CP could reduce mortality and increase viral clearance. Despite promising pilot studies, the benefits of CP treatment can only be clearly established through carefully designed RCTs. Conclusions There is developing support for CP therapy, particularly for patients who are critically ill or mechanically ventilated and resistant to antivirals and supportive care. These studies provide important lessons that should inform the planning of well-designed RCTs to generate more robust knowledge for the efficacy of CP in patients with COVID-19. Future research is necessary to fill the knowledge gap regarding prevention and treatment for patients with COVID-19 with CP while other therapeutics are being developed.

show abstract

Safety and efficacy of COVID‐19 convalescent plasma in severe pulmonary disease: A report of 17 patients

Cited by 15 publications

References 12 publications

A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China

A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China

Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Contact Info

Product

Resources

About